MX2019010651A - Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. - Google Patents

Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.

Info

Publication number
MX2019010651A
MX2019010651A MX2019010651A MX2019010651A MX2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A
Authority
MX
Mexico
Prior art keywords
delivery device
drug delivery
nauseogenic compound
administration
methods
Prior art date
Application number
MX2019010651A
Other languages
English (en)
Spanish (es)
Inventor
Young Andrew
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of MX2019010651A publication Critical patent/MX2019010651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019010651A 2017-03-08 2018-03-08 Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. MX2019010651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468399P 2017-03-08 2017-03-08
PCT/US2018/021594 WO2018165462A1 (en) 2017-03-08 2018-03-08 Apparatus and methods for administration of a nauseogenic compound from a drug delivery device

Publications (1)

Publication Number Publication Date
MX2019010651A true MX2019010651A (es) 2020-01-13

Family

ID=61692164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010651A MX2019010651A (es) 2017-03-08 2018-03-08 Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.

Country Status (10)

Country Link
US (1) US20200188479A1 (enExample)
EP (1) EP3592376A1 (enExample)
JP (2) JP2020510028A (enExample)
KR (1) KR20190126335A (enExample)
CN (1) CN110545838A (enExample)
AU (1) AU2018231249A1 (enExample)
CA (1) CA3055759A1 (enExample)
IL (1) IL269001A (enExample)
MX (1) MX2019010651A (enExample)
WO (1) WO2018165462A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
KR20230040943A (ko) * 2020-04-20 2023-03-23 아이투오 테라퓨틱스, 인코포레이티드 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575298B2 (ja) * 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
PL189289B1 (pl) 1996-02-02 2005-07-29 Alza Corp Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
KR100576583B1 (ko) 1997-12-22 2006-05-04 알자 코포레이션 서방성 약물 송달 장치용 속도 조절막
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
KR100568917B1 (ko) 1997-12-30 2006-04-07 알자 코포레이션 멤브레인 플러그를 갖는 익제 전달장치
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
CA2356860C (en) 1998-12-31 2006-11-07 Alza Corporation Osmotic delivery system having space efficient piston
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1328256B1 (en) 1999-12-21 2005-10-19 Alza Corporation Valve for osmotic devices
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
EP1613389B8 (en) 2003-03-31 2008-05-07 Intarcia Therapeutics, Inc. Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CA2595457A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
HRP20150186T1 (hr) 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
AU2007240313B2 (en) * 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
DK2462246T3 (da) * 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CA2797310C (en) * 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2015500823A (ja) * 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
CA2909045C (en) 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
WO2016037128A1 (en) * 2014-09-04 2016-03-10 Nano Precision Medical, Inc. Polymeric stabilizing formulations
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
MA53353A (fr) * 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
KR20190104039A (ko) * 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Also Published As

Publication number Publication date
JP2020510028A (ja) 2020-04-02
JP2023061945A (ja) 2023-05-02
KR20190126335A (ko) 2019-11-11
EP3592376A1 (en) 2020-01-15
IL269001A (en) 2019-10-31
US20200188479A1 (en) 2020-06-18
CN110545838A (zh) 2019-12-06
AU2018231249A1 (en) 2019-09-26
CA3055759A1 (en) 2018-09-13
WO2018165462A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
HK1248564A1 (zh) 用大麻素的局部区域神经影响性疗法
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MY199903A (en) Combination therapy with controlled-release cnp agonists
WO2015020943A3 (en) Digestive enzyme composition suitable for enteral administration
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
EP3590338A3 (en) Medical treatments based on anamorelin
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
MX2019010651A (es) Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2013012204A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
ZA202402868B (en) Treatment method for retinal degeneration
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito
MX2013012205A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
RU2015154876A (ru) Способ хирургического лечения диабетического макулярного отека с наличием витреомакулярной тракции
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.